Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.85
JNJ's Cash to Debt is ranked higher than
73% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. JNJ: 1.85 )
JNJ' s 10-Year Cash to Debt Range
Min: 0.17   Max: 6.28
Current: 1.85

0.17
6.28
Equity to Asset 0.58
JNJ's Equity to Asset is ranked higher than
67% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. JNJ: 0.58 )
JNJ' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.67
Current: 0.58

0.46
0.67
Interest Coverage 38.13
JNJ's Interest Coverage is ranked higher than
64% of the 490 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.59 vs. JNJ: 38.13 )
JNJ' s 10-Year Interest Coverage Range
Min: 19.77   Max: 230.91
Current: 38.13

19.77
230.91
F-Score: 7
Z-Score: 5.47
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.23
JNJ's Operating margin (%) is ranked higher than
95% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.55 vs. JNJ: 27.23 )
JNJ' s 10-Year Operating margin (%) Range
Min: 17.84   Max: 26.92
Current: 27.23

17.84
26.92
Net-margin (%) 21.15
JNJ's Net-margin (%) is ranked higher than
96% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.93 vs. JNJ: 21.15 )
JNJ' s 10-Year Net-margin (%) Range
Min: 12.52   Max: 21.65
Current: 21.15

12.52
21.65
ROE (%) 21.12
JNJ's ROE (%) is ranked higher than
95% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. JNJ: 21.12 )
JNJ' s 10-Year ROE (%) Range
Min: 17.02   Max: 30.17
Current: 21.12

17.02
30.17
ROA (%) 11.92
JNJ's ROA (%) is ranked higher than
93% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.06 vs. JNJ: 11.92 )
JNJ' s 10-Year ROA (%) Range
Min: 8.93   Max: 17.94
Current: 11.92

8.93
17.94
ROC (Joel Greenblatt) (%) 85.29
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.08 vs. JNJ: 85.29 )
JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 51.96   Max: 110.98
Current: 85.29

51.96
110.98
Revenue Growth (%) 3.90
JNJ's Revenue Growth (%) is ranked higher than
68% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. JNJ: 3.90 )
JNJ' s 10-Year Revenue Growth (%) Range
Min: 1.4   Max: 14.8
Current: 3.9

1.4
14.8
EBITDA Growth (%) -1.30
JNJ's EBITDA Growth (%) is ranked higher than
66% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.20 vs. JNJ: -1.30 )
JNJ' s 10-Year EBITDA Growth (%) Range
Min: -6.6   Max: 16.5
Current: -1.3

-6.6
16.5
EPS Growth (%) 0.20
JNJ's EPS Growth (%) is ranked higher than
70% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. JNJ: 0.20 )
JNJ' s 10-Year EPS Growth (%) Range
Min: -8.6   Max: 20.2
Current: 0.2

-8.6
20.2
» JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

JNJ Guru Trades in Q3 2013

Louis Moore Bacon 5,694 sh (New)
Joel Greenblatt 32,599 sh (New)
Ray Dalio 27,293 sh (New)
Richard Pzena 847,758 sh (+8050.74%)
Steven Cohen 151,123 sh (+611.8%)
Ruane Cunniff 74,495 sh (+420.69%)
Jim Simons 3,275,300 sh (+350.27%)
Paul Tudor Jones 7,100 sh (+195.83%)
Sarah Ketterer 426,250 sh (+45.3%)
John Rogers 127,576 sh (+33.75%)
Robert Olstein 92,000 sh (+2.22%)
Murray Stahl 31,214 sh (+1.34%)
Jean-Marie Eveillard 1,596,580 sh (+1.27%)
Mario Gabelli 409,421 sh (+0.82%)
James Barrow 17,194,257 sh (+0.22%)
Richard Snow 3,235 sh (+0.15%)
Yacktman Focused Fund 3,800,000 sh (unchged)
Jeff Auxier 97,577 sh (unchged)
Stanley Druckenmiller 129,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Michael Price 35,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Dodge & Cox 38,725 sh (unchged)
Richard Perry 388,897 sh (unchged)
Ken Fisher 10,143,775 sh (-0.17%)
Tweedy Browne 4,324,131 sh (-0.35%)
Tom Gayner 580,800 sh (-0.37%)
Bill Frels 1,815,415 sh (-0.99%)
Mark Hillman 30,829 sh (-1.02%)
PRIMECAP Management 13,813,887 sh (-1.3%)
Donald Yacktman 9,619,720 sh (-1.44%)
HOTCHKIS & WILEY 4,134,878 sh (-3.27%)
Manning & Napier Advisors, Inc 4,152,996 sh (-6.99%)
Jeremy Grantham 21,210,245 sh (-8.46%)
Pioneer Investments 3,879,715 sh (-8.53%)
Vanguard Health Care Fund 2,897,600 sh (-11.42%)
First Pacific Advisors 1,498,300 sh (-17.82%)
Steven Romick 1,425,000 sh (-17.87%)
John Hussman 202,650 sh (-19.79%)
Chris Davis 163,492 sh (-21.51%)
George Soros 1,267,000 sh (-50%)
Prem Watsa 2,941,741 sh (-50.27%)
Chuck Royce 13,500 sh (-66.42%)
» More
Q4 2013

JNJ Guru Trades in Q4 2013

Ray Dalio 113,193 sh (+314.73%)
Paul Tudor Jones 26,088 sh (+267.44%)
John Rogers 349,157 sh (+173.69%)
Stanley Druckenmiller 235,000 sh (+82.17%)
Jim Simons 5,498,400 sh (+67.87%)
Steven Cohen 224,813 sh (+48.76%)
Sarah Ketterer 559,450 sh (+31.25%)
Murray Stahl 32,614 sh (+4.49%)
Pioneer Investments 4,013,743 sh (+3.45%)
Richard Pzena 866,458 sh (+2.21%)
James Barrow 17,330,009 sh (+0.79%)
Chris Davis 164,755 sh (+0.77%)
Jean-Marie Eveillard 1,607,280 sh (+0.67%)
Mario Gabelli 411,797 sh (+0.58%)
Bill Frels 1,821,701 sh (+0.35%)
First Pacific Advisors 1,501,800 sh (+0.23%)
Ken Fisher 10,165,567 sh (+0.21%)
Brian Rogers 4,633,000 sh (unchged)
Steven Romick 1,425,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Richard Snow 3,235 sh (unchged)
Michael Price 35,000 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
George Soros Sold Out
Vanguard Health Care Fund Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
Tom Gayner 580,600 sh (-0.03%)
Donald Yacktman 9,610,642 sh (-0.09%)
Jeff Auxier 97,452 sh (-0.13%)
Dodge & Cox 38,625 sh (-0.26%)
Mark Hillman 30,746 sh (-0.27%)
Tweedy Browne 4,305,931 sh (-0.42%)
Manning & Napier Advisors, Inc 4,132,692 sh (-0.49%)
Ruane Cunniff 74,094 sh (-0.54%)
PRIMECAP Management 13,689,047 sh (-0.9%)
Robert Olstein 91,000 sh (-1.09%)
Jeremy Grantham 19,775,624 sh (-6.76%)
HOTCHKIS & WILEY 3,819,961 sh (-7.62%)
Richard Perry 342,277 sh (-11.99%)
Chuck Royce 11,300 sh (-16.3%)
John Hussman 102,650 sh (-49.35%)
Prem Watsa 84,700 sh (-97.12%)
» More
Q1 2014

JNJ Guru Trades in Q1 2014

RS Investment Management 7,228 sh (New)
George Soros 102,500 sh (New)
Joel Greenblatt 7,496 sh (New)
John Buckingham 45,697 sh (New)
Ray Dalio 262,993 sh (+132.34%)
First Pacific Advisors 1,936,200 sh (+28.93%)
Steven Romick 1,835,000 sh (+28.77%)
Sarah Ketterer 696,350 sh (+24.47%)
Robert Olstein 110,000 sh (+20.88%)
Manning & Napier Advisors, Inc 4,727,195 sh (+14.39%)
Bill Frels 2,011,442 sh (+10.42%)
John Rogers 366,918 sh (+5.09%)
HOTCHKIS & WILEY 3,932,985 sh (+2.96%)
Ruane Cunniff 75,794 sh (+2.29%)
Jean-Marie Eveillard 1,617,567 sh (+0.64%)
Richard Snow 3,245 sh (+0.31%)
Richard Pzena 868,139 sh (+0.19%)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Perry 342,277 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Dodge & Cox 38,625 sh (unchged)
Michael Price 35,000 sh (unchged)
Prem Watsa 84,700 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Chris Davis Sold Out
Stanley Druckenmiller Sold Out
Jeff Auxier 97,237 sh (-0.22%)
Donald Yacktman 9,572,850 sh (-0.39%)
Tweedy Browne 4,269,206 sh (-0.85%)
Murray Stahl 32,329 sh (-0.87%)
Tom Gayner 574,200 sh (-1.1%)
Ken Fisher 9,977,824 sh (-1.85%)
James Barrow 16,953,029 sh (-2.18%)
Pioneer Investments 3,891,373 sh (-3.05%)
Mario Gabelli 395,061 sh (-4.06%)
PRIMECAP Management 12,300,986 sh (-10.14%)
Jeremy Grantham 17,574,048 sh (-11.13%)
Chuck Royce 7,300 sh (-35.4%)
Jim Simons 2,659,200 sh (-51.64%)
Paul Tudor Jones 4,000 sh (-84.67%)
Steven Cohen 9,821 sh (-95.63%)
John Hussman 2,650 sh (-97.42%)
» More
Q2 2014

JNJ Guru Trades in Q2 2014

Paul Tudor Jones 5,700 sh (+42.5%)
John Rogers 522,727 sh (+42.46%)
Richard Pzena 1,155,666 sh (+33.12%)
Sarah Ketterer 837,250 sh (+20.23%)
Jim Simons 3,145,500 sh (+18.29%)
Pioneer Investments 4,329,534 sh (+11.26%)
RS Investment Management 7,928 sh (+9.68%)
Ken Fisher 10,448,448 sh (+4.72%)
John Buckingham 46,512 sh (+1.78%)
Manning & Napier Advisors, Inc 4,769,286 sh (+0.89%)
James Barrow 17,065,230 sh (+0.66%)
Jean-Marie Eveillard 1,623,482 sh (+0.37%)
Ruane Cunniff 76,012 sh (+0.29%)
Tom Gayner 574,200 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Dodge & Cox 38,625 sh (unchged)
Caxton Associates 100,000 sh (unchged)
Richard Snow 3,245 sh (unchged)
Richard Perry 342,277 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Michael Price 35,000 sh (unchged)
Prem Watsa 84,700 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce Sold Out
PRIMECAP Management 12,242,420 sh (-0.48%)
Bill Frels 1,996,199 sh (-0.76%)
Tweedy Browne 4,196,224 sh (-1.71%)
Murray Stahl 31,683 sh (-2%)
Jeff Auxier 94,101 sh (-3.23%)
First Pacific Advisors 1,851,700 sh (-4.36%)
Steven Romick 1,750,000 sh (-4.63%)
Donald Yacktman 9,045,902 sh (-5.5%)
Mario Gabelli 373,186 sh (-5.54%)
Yacktman Focused Fund 3,300,000 sh (-13.16%)
Jeremy Grantham 14,297,233 sh (-18.65%)
Robert Olstein 87,000 sh (-20.91%)
John Hussman 1,325 sh (-50%)
George Soros 50,000 sh (-51.22%)
HOTCHKIS & WILEY 1,426,614 sh (-63.73%)
Ray Dalio 65,893 sh (-74.94%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Yacktman Focused Fund 2014-06-30 Reduce -13.16%0.51%$96.54 - $105.76 $ 108.197%3300000
Donald Yacktman 2014-06-30 Reduce -5.5%0.21%$96.54 - $105.76 $ 108.197%9045902
Tweedy Browne 2014-06-30 Reduce -1.71%0.17%$96.54 - $105.76 $ 108.197%4196224
Ray Dalio 2014-06-30 Reduce -74.94%0.16%$96.54 - $105.76 $ 108.197%65893
George Soros 2014-06-30 Reduce -51.22%0.05%$96.54 - $105.76 $ 108.197%50000
John Hussman 2014-06-30 Reduce -50%0.01%$96.54 - $105.76 $ 108.197%1325
Joel Greenblatt 2014-06-30 Sold Out 0.01%$96.54 - $105.76 $ 108.197%0
John Hussman 2014-03-31 Reduce -97.42%0.65%$86.62 - $97.44 $ 108.1917%2650
PRIMECAP Management 2014-03-31 Reduce -10.14%0.15%$86.62 - $97.44 $ 108.1917%12300986
Ray Dalio 2014-03-31 Add 132.34%0.12%$86.62 - $97.44 $ 108.1917%262993
George Soros 2014-03-31 New Buy0.1%$86.62 - $97.44 $ 108.1917%102500
Joel Greenblatt 2014-03-31 New Buy0.01%$86.62 - $97.44 $ 108.1917%7496
Prem Watsa 2013-12-31 Reduce -97.12%15.54%$85.61 - $95.63 $ 108.1917%84700
George Soros 2013-12-31 Sold Out 1.2%$85.61 - $95.63 $ 108.1917%0
Vanguard Health Care Fund 2013-12-31 Sold Out 0.85%$85.61 - $95.63 $ 108.1917%0
John Hussman 2013-12-31 Reduce -49.35%0.48%$85.61 - $95.63 $ 108.1917%102650
Joel Greenblatt 2013-12-31 Sold Out 0.09%$85.61 - $95.63 $ 108.1917%0
Ray Dalio 2013-12-31 Add 314.73%0.06%$85.61 - $95.63 $ 108.1917%113193
Prem Watsa 2013-09-30 Reduce -50.27%10.26%$86.17 - $94.39 $ 108.1920%2941741
George Soros 2013-09-30 Reduce -50%1.2%$86.17 - $94.39 $ 108.1920%1267000
John Hussman 2013-09-30 Reduce -19.79%0.2%$86.17 - $94.39 $ 108.1920%202650
Vanguard Health Care Fund 2013-09-30 Reduce -11.42%0.11%$86.17 - $94.39 $ 108.1920%2897600
Joel Greenblatt 2013-09-30 New Buy0.09%$86.17 - $94.39 $ 108.1920%32599
Ruane Cunniff 2013-09-30 Add 420.69%0.03%$86.17 - $94.39 $ 108.1920%74495
Ray Dalio 2013-09-30 New Buy0.02%$86.17 - $94.39 $ 108.1920%27293
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Johnson & Johnson

John Rogers' Ariel Fund Comments on Johnson & Johnson - Feb 28, 2014

Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled...

After its slide in the current century, Johnson & Johnson took the opportunity to reinvigorate itself. Alex Gorsky, who became CEO in 2012, led a major transformation; he charged his new operations head, Sandra Peterson, with structural improvements across the company. On the pharmaceutical side, it refocused its Research & Development (R&D) on blockbuster segments such as anti-coagulants and oncology. In its medical technology division, the company boldly exited the underperforming drug-eluding stent business and deployed foreign cash through the acquisition of high-margin specialty implant maker Synthes, a Swiss company. Johnson & Johnson even bolstered its consumer brands such as Neutrogena and Band-Aid, which offer lower margins but steady cash flows. More importantly, it has gotten past the embarrassing 2010 recalls of the children's versions of Tylenol, Motrin, Zyrtec and Benadryl, and all four are now back on the shelves. We always look forward, even when analyzing a 127-year old company, and at this point see a lean, mean heavyweight ready to compete.

From John Rogers (Trades, Portfolio)' Ariel International Fund & Ariel Global Fund fourth quarter 2013 commentary by Rupal J. Bhansali.

Check out latest stock trades

Top Ranked Articles about Johnson & Johnson

Top Five Mega-Cap Stocks That Gurus Like
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mega cap companies which are held by the most gurus. The following five mega-capped companies are held by the largest number of gurus during the past quarter. Read more...
Money Managers Tweedy Browne Report Largest Stocks, Topped by Johnson & Johnson
Tweedy Browne (Trades, Portfolio) is a 93-year-old fund which focuses on undervalued securities, and which gained its investment approach from the late Benjamin Graham. The fund is owned and managed by William Browne, Thomas Shrager, John Spears and Robert Wyckoff, Jr. Read more...
Investor Steven Romick's Top 5 Increases of First Quarter
FPA Crescent Fund’s Steven Romick (Trades, Portfolio) in the first quarter preferred to have cash ready to put to work in case volatility hit the markets, rather than buy new stocks. He believes a period of volatility – and the low-priced opportunities it would bring with it – could occur soon. Read more...
Gurus’ Most-Sold Fourth Quarter Stocks - Each at a 10-Year High
In the fourth quarter of 2013, the S&P 500 hit record highs, while the majority of corporations (95) reported negative EPS guidance, and 12 issued positive EPS guidance, according to FactSet Research. The estimated earnings growth rate for all corporations for the quarter was estimated to be 6.3%, according to FactSet. The Financial sector led growth, increasing earnings by 24.2%. Energy lagged all sectors, with an 8% decline in earnings. Read more...
Weekly 52-Week Highs Highlight: MAR, JNJ, HAL, BHI
According to GuruFocus list of 52-week highs; Marriott International Inc., Johnson & Johnson, Halliburton Company and Baker Hughes Inc. have all reached their 52-week highs. Read more...
Top Owned Health Care Stocks of the Fourth Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the fourth quarter, the following five health care companies are held by the largest number of gurus. Read more...
John Rogers' Ariel Fund Comments on Johnson & Johnson
Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled... Read more...
Money Managers Tweedy Browne Report New Stocks, Topped by Johnson & Johnson
Tweedy Browne (Trades, Portfolio) is a 93-year-old fund which focuses on undervalued securities, and which gained its investment approach from the late Benjamin Graham. The fund is owned and managed by William Browne, Thomas Shrager, John Spears and Robert Wyckoff, Jr. Read more...
Top Five Guru-Held Health Care Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the third quarter, the following five health care companies are held by the largest number of gurus. Read more...
Law of Diminishing Returns - Warren Buffett's Advised Experiment
Warren Buffett gave the following example as a law of diminishing returns and future revenue growth, and I decided to take him up on it: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.00
JNJ's P/E(ttm) is ranked higher than
90% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.90 vs. JNJ: 20.00 )
JNJ' s 10-Year P/E(ttm) Range
Min: 10.5   Max: 24.45
Current: 20

10.5
24.45
P/B 3.92
JNJ's P/B is ranked higher than
68% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. JNJ: 3.92 )
JNJ' s 10-Year P/B Range
Min: 2.68   Max: 6.21
Current: 3.92

2.68
6.21
P/S 4.23
JNJ's P/S is ranked higher than
68% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. JNJ: 4.23 )
JNJ' s 10-Year P/S Range
Min: 2.16   Max: 4.28
Current: 4.23

2.16
4.28
PFCF 19.67
JNJ's PFCF is ranked higher than
94% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. JNJ: 19.67 )
JNJ' s 10-Year PFCF Range
Min: 10.29   Max: 24.69
Current: 19.67

10.29
24.69
EV-to-EBIT 14.51
JNJ's EV-to-EBIT is ranked higher than
90% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.14 vs. JNJ: 14.51 )
JNJ' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 18.7
Current: 14.51

8.4
18.7
Shiller P/E 23.01
JNJ's Shiller P/E is ranked higher than
89% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.02 vs. JNJ: 23.01 )
JNJ' s 10-Year Shiller P/E Range
Min: 13.11   Max: 31.12
Current: 23.01

13.11
31.12
Current Ratio 2.47
JNJ's Current Ratio is ranked higher than
73% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. JNJ: 2.47 )
JNJ' s 10-Year Current Ratio Range
Min: 1.2   Max: 2.69
Current: 2.47

1.2
2.69
Quick Ratio 2.13
JNJ's Quick Ratio is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. JNJ: 2.13 )
JNJ' s 10-Year Quick Ratio Range
Min: 0.94   Max: 2.37
Current: 2.13

0.94
2.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.52
JNJ's Dividend Yield is ranked higher than
80% of the 485 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. JNJ: 2.52 )
JNJ' s 10-Year Dividend Yield Range
Min: 1.64   Max: 3.84
Current: 2.52

1.64
3.84
Dividend Payout 0.50
JNJ's Dividend Payout is ranked higher than
87% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. JNJ: 0.50 )
JNJ' s 10-Year Dividend Payout Range
Min: 0.29   Max: 13.89
Current: 0.5

0.29
13.89
Dividend growth (3y) 7.10
JNJ's Dividend growth (3y) is ranked higher than
83% of the 356 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. JNJ: 7.10 )
JNJ' s 10-Year Dividend growth (3y) Range
Min: 7.1   Max: 17.1
Current: 7.1

7.1
17.1
Yield on cost (5-Year) 3.57
JNJ's Yield on cost (5-Year) is ranked higher than
87% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. JNJ: 3.57 )
JNJ' s 10-Year Yield on cost (5-Year) Range
Min: 2.34   Max: 5.49
Current: 3.57

2.34
5.49
Share Buyback Rate -1.00
JNJ's Share Buyback Rate is ranked higher than
77% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. JNJ: -1.00 )
JNJ' s 10-Year Share Buyback Rate Range
Min: 2   Max: -4.9
Current: -1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.57
JNJ's Price/Tangible Book is ranked higher than
59% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.72 vs. JNJ: 10.57 )
JNJ' s 10-Year Price/Tangible Book Range
Min: 6.25   Max: 20.45
Current: 10.57

6.25
20.45
Price/DCF (Projected) 1.63
JNJ's Price/DCF (Projected) is ranked higher than
89% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.02 vs. JNJ: 1.63 )
JNJ' s 10-Year Price/DCF (Projected) Range
Min: 0.84   Max: 3.6
Current: 1.63

0.84
3.6
Price/Median PS Value 1.32
JNJ's Price/Median PS Value is ranked higher than
68% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. JNJ: 1.32 )
JNJ' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 1.88
Current: 1.32

0.69
1.88
Price/Graham Number 3.04
JNJ's Price/Graham Number is ranked higher than
77% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.67 vs. JNJ: 3.04 )
JNJ' s 10-Year Price/Graham Number Range
Min: 1.95   Max: 6.12
Current: 3.04

1.95
6.12
Earnings Yield (Greenblatt) 6.90
JNJ's Earnings Yield (Greenblatt) is ranked higher than
85% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. JNJ: 6.90 )
JNJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.3   Max: 11.9
Current: 6.9

5.3
11.9
Forward Rate of Return (Yacktman) 4.33
JNJ's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. JNJ: 4.33 )
JNJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.3   Max: 18.2
Current: 4.33

1.3
18.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT » details
Traded in other countries:JNJ.Germany
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. It is a holding company, which has more than 250 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients. RISPERDAL CONSTA, a long-acting injectable, and INVEGATM Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN and FLOXIN, both in the anti-infective field; CONCERTA, a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal a treatment for chronic pain that offers a novel delivery system. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used mainly in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. In a
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
The 4% Rule Examined Sep 11 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
Rainy Day Dividend Stocks Sep 10 2014 
3 Dividend Stocks For Retirement Sep 09 2014 
Think Like An Owner Aug 27 2014 
High-Yield, High-Return Investments To Increase Income While Waiting On Dividend Growth Aug 27 2014 
Here's Why Johnson & Johnson Is a Good Investment at 52-Week Highs Aug 25 2014 
The Most Important Financial Statement When Selecting Dividend Growth Stocks Aug 21 2014 
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
A Strong Candidate for Investor´s Portfolios Aug 12 2014 

More From Our Partners
Stock Market News for September 19, 2014 - Market News Sep 19 2014 - ZACKS

More From Other Websites
Today's Market Thorns, Roses, and All Time Highs... Sep 19 2014
Gilead's Zydelig Approved In EU; Imbruvica In Wings Sep 19 2014
Today's Market Thorns, Roses and All Time Highs... Sep 18 2014
Corporate bond ratings do not discern risk Sep 18 2014
AstraZeneca and Eli Lilly to unite for Alzheimer's drug challenge Sep 16 2014
The Keys In This Market: Income & Growth Sep 16 2014
Lawyer grills DePuy executive over safety studies for Pinnacle hips Sep 15 2014
3 Companies Investing In Stem Cell Research Sep 14 2014
Adapting Listerine to a Global Market Sep 12 2014
Addressing Disengagement And Depression Lifts Workers Sep 12 2014
Insider Trading Alert - JNJ, EL And GPI Traded By Insiders Sep 12 2014
BAT's novel e-cigarette rival wins UK medical approval Sep 12 2014
Medivation Eyes Blockbuster As Cancer Drug Gets An OK Sep 11 2014
J&J Plans for the Future by Trimming Pension Benefits for New Hires Sep 11 2014
[video] As Life Expectancies Rise, Death Care Stocks Offer Opportunities Sep 09 2014
Johnson & Johnson Should Ignore Those Breakup Calls Sep 09 2014
The Zacks Analyst Blog Highlights: Intel, Advanced Micro Devices, Johnson & Johnson, Bayer and... Sep 08 2014
Experimental Ebola vaccine protects monkeys for 10 months Sep 07 2014
Stock Market Video Analysis 9/5/14 Sep 05 2014
J&J Ordered to Pay $3.27 Million Over Mesh Implant Sep 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK